American Association for Cancer Research
Browse
10780432ccr200054-sup-235134_2_supp_6150218_q6z46d.pptx (222.61 kB)

Supplementary Figure 8 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Download (222.61 kB)
figure
posted on 2023-03-31, 22:09 authored by Benoit You, Patrick Robelin, Michel Tod, Christophe Louvet, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Michel Fabbro, Christophe Desauw, Nathalie Bonichon-Lamichhane, Jean-Emmanuel Kurtz, Philippe Follana, Marianne Leheurteur, Francesco Del Piano, Gwénael Ferron, Gaëtan De Rauglaudre, Isabelle Ray-Coquard, Pierre Combe, Annick Chevalier-Place, Florence Joly, Alexandra Leary, Eric Pujade-Lauraine, Gilles Freyer, Olivier Colomban

Explorative analyses of progression-free survival according to standardized KELIM terciles (upper vs intermediate + lower) and disease-risk groups, adjusted from Oza et al. Med.: Median; std: standardized; NR: not reached; 95% CI: 95% confidence interval; P: Log-rank test.

History

ARTICLE ABSTRACT

In patients with ovarian cancer receiving neoadjuvant chemotherapy, the first-line treatment success will depend on both the tumor-primary chemosensitivity and the completeness of interval debulking surgery (IDS). The modeled CA-125 ELIMination rate constant K (KELIM), calculated with the CA-125 longitudinal kinetics during the first 100 chemotherapy days, is a validated early marker of tumor chemosensitivity. The objective was to investigate the role of the chemosensitivity relative to the success of first-line medical–surgical treatment. The CA-125 concentrations were prospectively measured in the randomized phase II trial CHIVA (NCT01583322, carboplatin–paclitaxel regimen ± nintedanib, and IDS, n = 188 patients). The KELIM predictive value regarding the tumor response rate, likelihood of complete IDS, risk of subsequent platinum-resistant relapse (PtRR), progression-free survival (PFS), and overall survival (OS) was assessed using univariate and multivariate tests. The data from 134 patients were analyzed. KELIM was an independent and major predictor of subsequent PtRR risk, and of survivals. The final logistic regression model, including KELIM [OR = 0.13; 95% confidence interval (CI), 0.03–0.49] and complete IDS (no vs. yes, OR = 0.30; 95% CI, 0.11–0.76) highlights the preponderant role of chemosensitivity on the success of the first-line treatment. In patients with highly chemosensitive diseases, the patient prognosis was driven more by the chemotherapy-induced antitumor effects than by the surgery. The tumor-primary chemosensitivity, assessed by the modeled CA-125 KELIM calculated during neoadjuvant chemotherapy (http://www.biomarker-kinetics.org/CA-125-neo), may be a major parameter to consider for decision-making regarding IDS attempt, and selecting patients for treatments meant to reverse the primary chemoresistance.See related commentary by May and Oza, p. 4432